Effects of l-carnitine Supplement on Serum Amyloid A and Vascular Inflammation Markers in Hemodialysis Patients: A Randomized Controlled Trial

Tabibi, H. and Hakeshzadeh, F. and Hedayati, M. and Malakoutian, T. (2011) Effects of l-carnitine Supplement on Serum Amyloid A and Vascular Inflammation Markers in Hemodialysis Patients: A Randomized Controlled Trial. Journal of Renal Nutrition, 21 (6). pp. 485-491.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Objective: We studied the effects of l-carnitine supplement on serum amyloid A (SAA), a systemic inflammation marker, and vascular inflammation markers in hemodialysis patients. Design: This was a randomized, double-blind, placebo-controlled trial. Setting: The study was performed in Soodeh Hemodialysis Center in Islamshahr, Iran. Patients: We included 36 hemodialysis patients (15 men and 21 women). Intervention: The patients on hemodialysis were randomly assigned to either a carnitine or a placebo group. Patients in the carnitine group received 1,000 mg/day oral l-carnitine for 12 weeks, whereas patients in the placebo group received a corresponding placebo during the study. Main Outcome Measures: Serum free carnitine, SAA, soluble intercellular adhesion molecule type 1, soluble intercellular adhesion molecule type 2, soluble vascular cell adhesion molecule type 1, sE-selectin, sP-selectin, and oxidized low-density lipoprotein were measured at baseline and at the end of week 12 of the study. Results: Mean serum free carnitine concentration increased significantly to 150 of baseline in the carnitine group at the end of week 12 (P < .001), whereas serum SAA showed a significant 32 decrease (P < .001). No significant changes were observed in the serum concentrations of free carnitine and SAA in the placebo group during the study. There were no significant differences between the two groups in mean changes in serum soluble intercellular adhesion molecule type 1, soluble intercellular adhesion molecule type 2, soluble vascular cell adhesion molecule type 1, sE-selectin, sP-selectin, and oxidized low-density lipoprotein concentrations. Conclusion: The study indicates that l-carnitine supplement reduces serum SAA, which is a risk factor for cardiovascular diseases in hemodialysis patients, but has no effect on vascular inflammation markers. © 2011 National Kidney Foundation, Inc.

Item Type: Article
Additional Information: cited By 11
Uncontrolled Keywords: biological marker; carnitine; endothelial leukocyte adhesion molecule 1; intercellular adhesion molecule 1; low density lipoprotein; oxidized low density lipoprotein; PADGEM protein; serum amyloid A; vascular cell adhesion molecule 1, adult; aged; article; blood; cardiovascular disease; clinical trial; controlled clinical trial; controlled study; diet supplementation; double blind procedure; drug effect; female; human; inflammation; Iran; male; middle aged; pathophysiology; randomized controlled trial; renal replacement therapy; risk factor, Adult; Aged; Biological Markers; Cardiovascular Diseases; Carnitine; Dietary Supplements; Double-Blind Method; E-Selectin; Female; Humans; Inflammation; Intercellular Adhesion Molecule-1; Iran; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Vascular Cell Adhesion Molecule-1
Subjects: WG Cardiovascular System
WJ Urogenital System
QV Pharmacology
Depositing User: somayeh pourmorteza
Date Deposited: 05 Jan 2019 09:48
Last Modified: 05 Jan 2019 09:48
URI: http://eprints.iums.ac.ir/id/eprint/7353

Actions (login required)

View Item View Item